Retatrutide (LY3437943) is a 39-residue synthetic peptide engineered to activate all three incretin/glucagon-axis receptors: GLP-1R, GIPR, and GCGR. The C20 fatty-diacid attachment confers albumin binding and an extended functional half-life. The combined receptor activity drives a distinct downstream signaling profile relative to dual or mono-agonists.
Each vial is lyophilized from acetate buffer at pH 4.0, sealed under nitrogen, and shipped ~4 days from our lab.
Research applications
Triple-receptor (GLP-1R/GIPR/GCGR) activation studies, comparative cAMP and β-arrestin recruitment screens versus tirzepatide and semaglutide, in-vivo metabolic phenotype models, and lipolytic-pathway investigations. Compatible with HEK293 and CHO cells expressing the relevant receptors.
Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.
Identity
Parameter
Value
Sequence
Synthetic 39-residue triagonist analog with γGlu-C20 lipid modification
Molecular formula
C₂₂₁H₃₄₃N₅₃O₆₅
Molecular weight
4731.42 g/mol
CAS number
2381089-83-2
Length
39 residues
Quality
Test
Specification
HPLC purity
99.733%
Bioburden
< 10 CFU/g
Residual TFA
< 1.0%
Lot LM-2777
Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Independently tested by Testides (report LUME-RETA-10-061626). Retain samples held under storage spec for five years from release date.
Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0-2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.
Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.
Storage after reconstitution
Reconstituted solution is stable for 28 days at 2-8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.
Selected references
Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.
Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526.
Rosenstock J et al. Retatrutide in adults with type 2 diabetes. Lancet. 2023;402(10401):529-544.
Retatrutide is a triagonist of GLP-1, GIP, and glucagon receptors, classified within the tri-receptor activation pathway. Structurally it is a 39-residue triagonist with γGlu-C20 lipid modification. Coskun et al. (2022) and Jastreboff et al. (2023) characterized retatrutide as the first clinically validated triple agonist of the GLP-1, GIP, and glucagon receptors. Its combined receptor activity drives a distinct downstream signaling profile relative to dual or mono-agonists.
In an in-vitro setting, Retatrutide interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable until reconstituted.
Common research applications
In-vitro receptor-binding and dose-response screens against the tri-receptor activation target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging Retatrutide's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.
Storage & handling
Retatrutide arrives lyophilized in Canada Post (~4 days). On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.
References
Coskun T et al. Cell Metab. 2022;34(9):1234-47.
Jastreboff AM et al. N Engl J Med. 2023;389(6):514-26.
Rosenstock J et al. Lancet. 2023;402(10401):529-44.
For laboratory research only. Retatrutide is sold strictly as an in-vitro reference standard. Sold as an in-vitro reference standard, not as a Health Canada or FDA-approved therapeutic.
